Prognostic Value Of Re-TURB Of High Risk Non Invasive Bladder Cancer

Main Category: Urology / Nephrology
Also Included In: Cancer / Oncology
Article Date: 28 Jun 2008 - 3:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


ORLANDO, FL (UroToday.com) - The authors evaluated the usefulness of second TURB and whether pathological outcomes of ReTUR have a prognostic impact on recurrence and progression of primitive T1G3 bladder cancer.

In this study patients with newly diagnosed T1G3 Transitional cell carcinoma of bladder underwent ReTUR 4-6 weeks following the initial TUR. Patients with muscle invasive disease underwent radical cystectomy; those with superficial residual (SRT) and those with no residual tumor (NRT) received a intravesical BCG therapy. In order to evaluate the prognostic significance of ReTUR outcomes, the authors compared recurrence rate, progression rate and recurrence free survival in SRT patients and NRT patients at restaging TUR.

From January 2002 to March 2007 91 patients were enrolled in the study. Restaging TUR revealed residual cancer in 48% of patients. At mean follow up of 27.2 19,8 months, there was statistically significant difference in recurrence rate, progression rate and disease-free survival between no residual tumor patients and patients with non-invasive residual disease (see table)

The authors conclude that ReTUR of T1G3 TCC allows identification of patients with residual and understaged tumors. The outcomes of ReTUR have a prognostic impact on recurrence rate and disease-free survival.

Presented by Roberto C Sanseverino, MD, Antonio Campitelli, MD, Giorgio Napodano, MD, Antonio Barela, MD, Giuseppe Contaldo, MD, at the Annual Meeting of the American Urological Association (AUA) - May 17 - 22, 2008. Orange County Convention Center - Orlando, Florida, USA.

Reported by UroToday.com Contributing Editor David P. Wood, MD

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to: www.urotoday.com

Copyright © 2008 - UroToday

Article adapted by Medical News Today from original press release.
Visit our urology / nephrology section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Urotoday. "Prognostic Value Of Re-TURB Of High Risk Non Invasive Bladder Cancer." Medical News Today. MediLexicon, Intl., 28 Jun. 2008. Web.
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/113147.php>

APA
Urotoday. (2008, June 28). "Prognostic Value Of Re-TURB Of High Risk Non Invasive Bladder Cancer." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/113147.php.

Please note: If no author information is provided, the source is cited instead.


Urology / Nephrology

Most Popular Articles



Follow Our Urology News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Urology / Nephrology Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »